Review
doi: 10.1016/0753-3322(92)90004-q.
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer
Affiliations
- PMID: 1363977
- DOI: 10.1016/0753-3322(92)90004-q
Item in Clipboard
Review
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer
Biomed Pharmacother.
1992.
Abstract
The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed. New therapeutic approaches utilizing antagonistic analogs of LH-RH such as SB-75 (Cetrorelix) have been described. Analogs of LH-RH chemically linked to various cytotoxic radicals are also being developed. Combinations of LH-RH agonists or antagonists with superactive somatostatin analogues such as Octastatin (RC-160) or with bombesin/GRP antagonists are being investigated in order to delay or prevent the relapse and improve the therapy for prostate cancer.
Similar articles
-
Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.Cancer. 1993 Dec 1;72(11):3263-70. doi: 10.1002/1097-0142(19931201)72:11<3263::aid-cncr2820721122>3.0.co;2-v. Cancer. 1993. PMID: 8242552
-
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.Prostate. 1997 Aug 1;32(3):164-72. doi: 10.1002/(sici)1097-0045(19970801)32:3<164::aid-pros2>3.0.co;2-l. Prostate. 1997. PMID: 9254895
-
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.Proc Natl Acad Sci U S A. 1987 Oct;84(20):7275-9. doi: 10.1073/pnas.84.20.7275. Proc Natl Acad Sci U S A. 1987. PMID: 2890164 Free PMC article.
-
Peptide analogs in the therapy of prostate cancer.Prostate. 2000 Oct 1;45(2):158-66. doi: 10.1002/1097-0045(20001001)45:2<158::aid-pros10>3.0.co;2-k. Prostate. 2000. PMID: 11027415 Review.
-
[History of clinical studies on hypothalamic hormone analogs in Mexico].Gac Med Mex. 2006 Jul-Aug;142(4):315-25. Gac Med Mex. 2006. PMID: 17022307 Review. Spanish.
Cited by
-
Predicting anticancer hyperfoods with graph convolutional networks.Hum Genomics. 2021 Jun 7;15(1):33. doi: 10.1186/s40246-021-00333-4. Hum Genomics. 2021. PMID: 34099048 Free PMC article.
-
Androgen deprivation and other treatments for advanced prostate cancer.Rev Urol. 2001;3 Suppl 2(Suppl 2):S59-68. Rev Urol. 2001. PMID: 16986000 Free PMC article.
-
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8864-8. doi: 10.1073/pnas.95.15.8864. Proc Natl Acad Sci U S A. 1998. PMID: 9671770 Free PMC article.
-
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.Br J Cancer. 1997;75(11):1585-92. doi: 10.1038/bjc.1997.271. Br J Cancer. 1997. PMID: 9184172 Free PMC article.
-
Neuroendocrine peptides in the prostate.Urol Res. 1995;23(2):81-7. doi: 10.1007/BF00307937. Urol Res. 1995. PMID: 7545839 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
